Clinical and Translational Oncology

, Volume 11, Issue 3, pp 126–137 | Cite as

Biology of BMP signalling and cancer

  • Moisés Blanco Calvo
  • Victoria Bolós Fernández
  • Vanessa Medina Villaamil
  • Guadalupe Aparicio Gallego
  • Silvia Díaz Prado
  • Enrique Grande Pulido
Educational Series Molecular and Cellular Biology of Cancer

Abstract

In recent years, it has been proposed that tumours are not homogeneous but composed of several cellular types like normal tissues. A cellular subtype, which is though to be the origin of tumours as well as their malignant properties (i.e., capacity for regrowth and metastasis), are the cancer stem cells (CSCs). CSCs, like normal stem cells, have a nearly unlimited capacity to self-renew and to proliferate so that are responsible, besides their same auto-perpetuation giving rise to the features previously depicted, also for the generation of the bulk of more differentiated cells in tumour. The altered behaviour of CSCs may be caused by the malfunction of a number of signalling pathways involved in normal embryonic development and in tissue homeostasis in adulthood. Among these signalling pathways are Wnt, Hedgehog, Notch and BMP pathways. In this review, we will focus on the study of molecular aspects of BMP signalling as well as its involvement in cancer.

Keywords

BMP pathway Signalling Cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Canalis E, Economides AN, Gazzerro E (2003) Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24:218–235PubMedCrossRefGoogle Scholar
  2. 2.
    Wan M, Cao X (2005) BMP signaling in skeletal development. Biochem Biophys Res Commun 328:651–657PubMedCrossRefGoogle Scholar
  3. 3.
    Lin SJ, Lerch TF, Cook RW et al (2006) The structural basis of TGF-protein, and activin ligand binding. Reproduction 132:179–190PubMedCrossRefGoogle Scholar
  4. 4.
    Shi Y, Massagué J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685–700PubMedCrossRefGoogle Scholar
  5. 5.
    Xiao YT, Xiang LX, Shao JZ (2007) Bone morphogenetic protein. Biochem Biophys Res Commun 362:550–553PubMedCrossRefGoogle Scholar
  6. 6.
    Gazzerro E, Canalis E (2006) Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 7:51–65PubMedCrossRefGoogle Scholar
  7. 7.
    Kochanowska I, Chaberek S, Wojtowicz A et al (2007) Expression of genes for bone morphogenetic proteins BMP-2, BMP-4 and BMP-6 in various parts of the human skeleton. BMC Musculoskelet Disord 8:128–137PubMedCrossRefGoogle Scholar
  8. 8.
    Varga AC, Wrana JL (2005) The disparate role of BMP in stem cell biology. Oncogene 24:5713–5721PubMedCrossRefGoogle Scholar
  9. 9.
    Balemans W, Van Hul W (2002) Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev Biol 250:231–250PubMedGoogle Scholar
  10. 10.
    Mazerbourg S, Sangkuhl K, Luo CW et al (2005) Identification of receptors and signaling pathways for orphan bone morphogenetic protein/growth differentiation factor ligands based on genomic analyses. J Biol Chem 280:32122–32132PubMedCrossRefGoogle Scholar
  11. 11.
    Kirkbride KC, Townsend TA, Bruinsma MW et al (2008) Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. J Biol Chem 283:7628–7637PubMedCrossRefGoogle Scholar
  12. 12.
    David L, Mallet C, Mazerbourg S et al (2007) Identification of BMP9 and BMP10 as functional activators of the orphan activin receptorlike kinase 1 (ALK1) in endothelial cells. Blood 109:1953–1961PubMedCrossRefGoogle Scholar
  13. 13.
    Shi W, Chang C, Nie S et al (2007) Endofin acts as a Smad anchor for receptor activation in BMP signaling. J Cell Sci 120:1216–1224PubMedCrossRefGoogle Scholar
  14. 14.
    Ross S, Hill CS (2008) How the Smads regulate transcription. Int J Biochem Cell Biol 40:383–408PubMedCrossRefGoogle Scholar
  15. 15.
    Massagué J, Seoane J, Wotton D (2005) Smad transcription factors. Genes Dev 19:2783–2810PubMedCrossRefGoogle Scholar
  16. 16.
    Davis BN, Hilyard AC, Lagna G, Hata A (2008) SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454:56–61PubMedCrossRefGoogle Scholar
  17. 17.
    Hogan BL (1996) Bone morphogenetic proteins in development. Curr Opin Genet Dev 6:432–438PubMedCrossRefGoogle Scholar
  18. 18.
    Lamm ML, Podlasek CA, Barnett DH et al (2001) Mesenchymal factor bone morphogenetic protein 4 restricts ductal budding and branching morphogenesis in the developing prostate. Dev Biol 232:301–314PubMedCrossRefGoogle Scholar
  19. 19.
    Grishina IB, Kim SY, Ferrara C et al (2005) BMP7 inhibits branching morphogenesis in the prostate gland and interferes with Notch signaling. Dev Biol 288:334–347PubMedCrossRefGoogle Scholar
  20. 20.
    Ye L, Lewis-Russell JM, Kyanaston HG, Jiang WG (2007) Bone morphogenetic proteins and their receptor signaling in prostate cancer. Histol Histopathol 22:1129–1147PubMedGoogle Scholar
  21. 21.
    Dai J, Kitagawa Y, Zhang J et al (2004) Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 64:994–999PubMedCrossRefGoogle Scholar
  22. 22.
    Davies SR, Watkins G, Douglas-Jones A et al (2007) Bone morphogenic proteins 1 to 7 in human breast carcinoma. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings 25[18S], Abstract 21154Google Scholar
  23. 23.
    Kodach LL, Wiercinska E, de Miranda NF et al (2008) The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. Gastroenterology 134:1332–1341PubMedCrossRefGoogle Scholar
  24. 24.
    Howe JR, Bair JL, Sayed MG et al (2001) Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 28:184–187PubMedCrossRefGoogle Scholar
  25. 25.
    Haramis AP, Begthel H, van den Born M et al (2004) De novo crypt formation and juvenile polyposis on BMP Inhibition in mouse intestine. Science 303:1684–1686PubMedCrossRefGoogle Scholar
  26. 26.
    Boulay JL, Mild G, Lowy A et al (2002) SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer. Br J Cancer 87:630–634PubMedCrossRefGoogle Scholar
  27. 27.
    Hardwick JC, Van Den Brink GR, Bleuming SA et al (2004) Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. Gastroenterology 126:111–121PubMedCrossRefGoogle Scholar

Copyright information

© Feseo 2009

Authors and Affiliations

  • Moisés Blanco Calvo
    • 1
  • Victoria Bolós Fernández
    • 2
  • Vanessa Medina Villaamil
    • 1
    • 3
  • Guadalupe Aparicio Gallego
    • 3
  • Silvia Díaz Prado
    • 1
    • 4
  • Enrique Grande Pulido
    • 2
  1. 1.Institute for Biomedical Research of A Coruña (INIBIC)A Coruña University HospitalA CoruñaSpain
  2. 2.Oncology Medical DepartmentPfizer SpainAlcobendas, MadridSpain
  3. 3.Oncology Research UnitA Coruña University HospitalA CoruñaSpain
  4. 4.Medicine DepartmentUniversity of A CoruñaA CoruñaSpain

Personalised recommendations